Regeneron has unique alternative to attach large-scale genomic and proteomic records cohorts to TriNetX’s industry-leading international community of digital well being document records
Collaboration will increase Regeneron’s world-leading genomic and proteomic EHR-linked database
Rising database will proceed to pressure drug discovery and building and empower AI coaching algorithms to ship virtual well being answers of the longer term for shoppers, sufferers and suppliers
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) — Regeneron Prescription drugs, Inc. (NASDAQ: REGN) and TriNetX® lately introduced a strategic collaboration to enhance Regeneron’s functions in drug discovery and building, in addition to new projects to ship virtual well being answers of the longer term for shoppers, sufferers and suppliers. Regeneron beneficial properties the unique alternative to attach large-scale genomic and proteomic records cohorts to TriNetX’s industry-leading phenotypic records community of roughly 300 million de-identified and anonymized sufferers. This collaboration will permit growth of Regeneron’s world-leading genomic and proteomic Digital Well being Document (EHR)-linked database, a key motive force of the corporate’s industry-leading therapeutics pipeline.
Below the collaboration, TriNetX will supply Regeneron with safe, approved get right of entry to to TriNetX’s present and long term de-identified well being records from roughly 300 million people (170 million of whom are in the US), sourced without delay from its international community of well being machine companions. With privacy-preserving strategies, Regeneron may have the aptitude to check a portion of TriNetX’s de-identified/anonymized records to genomic and proteomic records generated through the Regeneron Genetics Heart® (RGC®). Such matching will likely be performed in response to all acceptable records privateness rules, together with HIPAA and GDPR.
The RGC has advanced high-throughput and cost-efficient DNA sequencing and proteomics approaches to construct the arena’s biggest database of EHR-linked sequencing and proteomics records, in collaboration with over 150 existence sciences and healthcare collaborators all over the world. The collaboration with TriNetX will lend a hand Regeneron dramatically increase this already world-leading dataset to proceed to pressure drug discovery and building, whilst additionally empowering synthetic intelligence (AI) coaching algorithms to ship virtual well being answers of the longer term.
“We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data,” mentioned Jeff Margolis, TriNetX Govt Chairman. “Our team is gratified to be selected by Regeneron to provide access to TriNetX’s unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centers and other leading healthcare research sites.”
“This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world’s largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers,” mentioned Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Drugs. “TriNetX has built a world-leading platform with a proven track record of enabling research at scale. The RGC has spent over a decade generating genomic and now proteomic data and integrating these molecular data with longitudinal health records at large-scale. Combining these platforms brings together powerful human health databases with analytical and AI capabilities to help discover and develop innovative medicines for devastating diseases and create digital health solutions that we hope will transform our ability to predict, prevent and manage disease.”
“We are looking forward to working with the TriNetX team,” mentioned Andrew Deubler, Senior Vice President, RGC Leader Trade and Administrative Officer. “Our RGC strategic investments catalyze innovation, driving advancements in cutting-edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions. This deal represents the latest and one of our most significant collaborations, and we look forward to continuing to expand our network of top-tier partners as we pursue our mission.”
As a part of the collaboration, Regeneron will make investments as much as $200 million in TriNetX.
About TriNetX, LLC
TriNetX is the World Fact Engine for Higher Human Well being™ that makes advanced, real-world well being records simple to make use of. Information is sourced without delay from our rising international community of over 11,000 healthcare supplier places. TriNetX shoppers choose the knowledge supply, varieties, and breadth of information they want; the knowledge get right of entry to strategies they want; and the varieties of tool, human and system intelligence they want to practice – and mix those to resolve their trade goals. Consult with TriNetX at www.trinetx.com or apply TriNetX on LinkedIn to be informed extra.
About RegeneronRegeneron (NASDAQ: REGN) is a number one biotechnology corporate that invents, develops and commercializes life-transforming drugs for folks with severe illnesses. Based and led through physician-scientists, our distinctive skill to again and again and persistently translate science into drugs has ended in a large number of licensed therapies and product applicants in building, maximum of which have been homegrown in our laboratories. Our drugs and pipeline are designed to lend a hand sufferers with eye illnesses, allergic and inflammatory illnesses, most cancers, cardiovascular and metabolic illnesses, neurological illnesses, hematologic prerequisites, infectious illnesses, and uncommon illnesses.
Regeneron pushes the limits of clinical discovery and speeds up drug building the usage of our proprietary applied sciences, akin to VelociSuite®, which produces optimized absolutely human antibodies and new categories of bispecific antibodies. We’re shaping the following frontier of drugs with data-powered insights from the Regeneron Genetics Heart® and pioneering genetic drugs platforms, enabling us to spot cutting edge objectives and complementary approaches to doubtlessly deal with or treatment illnesses.
For more info, please discuss with www.Regeneron.com or apply Regeneron on LinkedIn, Instagram, Fb, YouTube or X.
Concerning the Regeneron Genetics CenterThe Regeneron Genetics Heart® (RGC®) is a genomic analysis initiative and a completely owned subsidiary of Regeneron. For over a decade, we’ve harnessed the facility of human genetics to find necessary new drugs, validate current analysis methods and optimize medical trials. We faucet into our rising database of greater than 3 million sequenced exomes and de-identified well being data the usage of proprietary records analytics, generation and human ingenuity to make significant organic discoveries at pace and scale. Our high-touch built-in fashion specializes in running intently with our collaborators to construct a dataset with significant cohorts. We use cutting edge applied sciences, akin to system finding out, to series exomes, align with well being data and carry out large-scale analyses to make significant associations between genes and illnesses. We practice our insights to steer Regeneron’s broader drug discovery and building efforts.
Regeneron Ahead-Taking a look Statements and Use of Virtual MediaThis press free up comprises forward-looking statements that contain dangers and uncertainties in terms of long term occasions and the longer term efficiency of Regeneron Prescription drugs, Inc. (“Regeneron” or the “Company”), and precise occasions or effects would possibly range materially from those forward-looking statements. Phrases akin to “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” permutations of such phrases, and equivalent expressions are supposed to spot such forward-looking statements, even supposing now not all forward-looking statements include those figuring out phrases. Those statements worry, and those dangers and uncertainties come with, amongst others, the character, timing, and conceivable luck and healing programs of goods advertised or in a different way commercialized through Regeneron and/or its collaborators or licensees (jointly, “Regeneron’s Products”) and product applicants being advanced through Regeneron and/or its collaborators or licensees (jointly, “Regeneron’s Product Candidates”), analysis and medical methods now underway or deliberate, and using human genetics in Regeneron’s analysis methods; the possibility, timing, and scope of accomplishing any of the expected milestones described on this press free up; the level to which the consequences from the analysis and building methods performed through Regeneron and/or its collaborators or licensees (akin to the ones that can consequence from Regeneron’s collaboration with TriNetX mentioned on this press free up) is also replicated in different research and/or result in development of product applicants to medical trials, healing programs, or regulatory approval; ongoing regulatory tasks and oversight impacting Regeneron’s Merchandise, analysis and medical methods, and trade, together with the ones in terms of affected person privateness; the possibility, timing, and scope of conceivable regulatory approval and industrial release of Regeneron’s Product Applicants and new indications for Regeneron’s Merchandise; uncertainty of the usage, marketplace acceptance, and industrial luck of Regeneron’s Merchandise and Regeneron’s Product Applicants and the have an effect on of research (whether or not performed through Regeneron or others and whether or not mandated or voluntary) on any of the foregoing; the facility of Regeneron’s collaborators, licensees, providers, or different 0.33 events (as acceptable) to accomplish production, filling, completing, packaging, labeling, distribution, and different steps associated with Regeneron’s Merchandise and Regeneron’s Product Applicants; the facility of Regeneron to regulate provide chains for more than one merchandise and product applicants and dangers related to price lists and different industry restrictions; questions of safety as a consequence of the management of Regeneron’s Merchandise and Regeneron’s Product Applicants in sufferers, together with severe headaches or uncomfortable side effects in reference to using Regeneron’s Merchandise and Regeneron’s Product Applicants in medical trials; determinations through regulatory and administrative governmental government which would possibly prolong or prohibit Regeneron’s skill to proceed to increase or commercialize Regeneron’s Merchandise and Regeneron’s Product Applicants; the provision and extent of compensation or copay help for Regeneron’s Merchandise from third-party payors and different 0.33 events, together with personal payor healthcare and insurance coverage methods, well being repairs organizations, pharmacy get advantages control corporations, and govt methods akin to Medicare and Medicaid; protection and compensation determinations through such payors and different 0.33 events and new insurance policies and procedures followed through such payors and different 0.33 events; adjustments to drug pricing laws and necessities and Regeneron’s pricing technique; different adjustments in rules, laws, and insurance policies affecting the healthcare {industry}; competing merchandise and product applicants (together with biosimilar merchandise) that can be awesome to, or less expensive than, Regeneron’s Merchandise and Regeneron’s Product Applicants; unanticipated bills; the prices of creating, generating, and promoting merchandise; the facility of Regeneron to satisfy any of its monetary projections or steerage and adjustments to the assumptions underlying the ones projections or steerage; the potential of any license, collaboration, or provide settlement, together with Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated corporations, as acceptable) in addition to the collaboration with TriNetX mentioned on this press free up, to be cancelled or terminated; the have an effect on of public well being outbreaks, epidemics, or pandemics on Regeneron’s trade; and dangers related to litigation and different complaints and govt investigations in terms of the Corporate and/or its operations (together with the pending civil complaints initiated or joined through the U.S. Division of Justice and the U.S. Legal professional’s Place of business for the District of Massachusetts), dangers related to highbrow assets of different events and pending or long term litigation touching on thereto (together with with out limitation the patent litigation and different comparable complaints in terms of EYLEA® (aflibercept) Injection), without equal end result of this kind of complaints and investigations, and the have an effect on any of the foregoing could have on Regeneron’s trade, potentialities, running effects, and fiscal situation. A extra entire description of those and different subject matter dangers will also be present in Regeneron’s filings with the U.S. Securities and Trade Fee, together with its Shape 10-Okay for the yr ended December 31, 2025. Any forward-looking statements are made in keeping with control’s present ideals and judgment, and the reader is cautioned to not depend on any forward-looking statements made through Regeneron. Regeneron does now not adopt any legal responsibility to replace (publicly or in a different way) any forward-looking commentary, together with with out limitation any monetary projection or steerage, whether or not on account of new data, long term occasions, or in a different way.
Regeneron makes use of its media and investor members of the family web site and social media retailers to post necessary details about the Corporate, together with data that can be deemed subject matter to traders. Monetary and different details about Regeneron is mechanically posted and is out there on Regeneron’s media and investor members of the family web site (https://investor.regeneron.com) and its LinkedIn web page (https://www.linkedin.com/corporate/regeneron-pharmaceuticals).
Regeneron
Media:
Ella Campbell
Buyers:
Vesna Tosic
TriNetX
Karen Tunks
